BL 1230

Drug Profile

BL 1230

Alternative Names: BL-1230

Latest Information Update: 14 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hebrew University of Jerusalem
  • Developer BioLineRx; Novartis
  • Class
  • Mechanism of Action Cannabinoid receptor CB2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Dry eyes

Most Recent Events

  • 21 Nov 2016 BioLineRx has patents pending for BL 1230 in the US, Europe and other countries (BioLineRx website, December 2016)
  • 21 Nov 2016 Preclinical trials in Dry eyes in Israel (Topical)
  • 21 Nov 2016 BioLineRx in-licenses BL 1230 from Yissum Research Development Company
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top